By Robert Bloder, Ascendia Pharma
Reducing costs and ensuring on-time delivery is a top priority for pharmaceutical companies aiming to bring their product to market ahead of their competition. Partnering with a CDMO that utilizes innovative technologies and a team of highly skilled, experienced scientists to advance a product through the development lifecycle with speed is key.
Ascendia Pharma’s innovative technology platforms enable them to work with lipid nanoparticles (LNPs) to enhance solubility and improve bioavailability – all while maintaining stability and product critical attributes – resulting in highly optimized drug formulation and delivery. Ascendia will also soon be offering Phase III and Commercial Supply Products, allowing them to produce prefilled syringes, vials, cartridges, and other deliverables at an even larger scale. Discover the opportunities for optimized drug formulation and delivery, as well as the commercial supply products on the horizon that can advance your therapy to the clinic and beyond.